Ainos, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Strategic pivot towards veldona and ai-powered point-of-care testing to continue in 2024 advancing veldona drug candidates to phase iii clinical studies expanding market of ai nose-powered voc-sensing technology with strategic partners nisd and inabata san diego, ca / accesswire / march 8, 2024 / ainos, inc. (nasdaq:aimd, aimdw) ("ainos", or the "company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic rna-driven preventative medicine, today announced its financial results for the year ended december 31, 2023. chun-hsien (eddy) tsai, chairman of the board, president, and chief executive officer of ainos, commented, "in 2023, we navigated a year of transition and successfully advanced the shift of our business model to align with the post-covid era.

Updated chemistry, manufacturing, and controls and stability test fulfill ainos' development objectives resolving the identified deficiencies will accelerate the timeline for ainos' other clinical trials san diego, ca / accesswire / february 5, 2024 / ainos, inc. (nasdaq: aimd, aimdw) ("ainos", or the "company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic rna-driven preventative medicine, today announced that it has submitted the clinical hold complete response to the u.s. food and drug administration (the "u.s. fda") for conducting a phase ii trial of its low-dose oral interferon (ifn)-alpha formulation, veldona®, for treatment of mild covid-19 symptoms...

The follow-on funding is a draw down from the $10 million private placement agreement entered into september 25 2023. use of proceeds include to advance planned veldona ind preparation and ai nose voc platform development with nisshinbo micro devices inc. (nisd) and taiwan inabata sangyo co. (inabata).

San diego, ca / accesswire / january 2, 2024 / ainos, inc. (nasdaq:aimd, aimdw) ("ainos", or the "company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic rna-driven preventative medicine, announced that on december 29, 2023, the company received a written notice from the nasdaq stock market ("nasdaq"). the notice informed ainos that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the "rule") for continued listing on the nasdaq capital market.

Mass production readiness targeted for 2h 2024 propelling ai nose technology towards broader industry adoption and advancing the mission of digitalizing smell san diego, ca / accesswire / december 26, 2023 / ainos, inc. (nasdaq: aimd, aimdw) ("ainos", or the "company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic rna-driven preventative medicine, today announced that it is initiating the second phase of co-development of a volatile organic compound (voc) sensing platform, powered by ai nose technology, in collaboration with nisshinbo micro devices inc. (nisd) and taiwan inabata sangyo co. (inabata)...

Ainos (NASDAQ: AIMD ) stock is rocketing higher on Friday with heavy trading of the healthcare company's shares. This has more than 7 million shares of the company's stock changing hands as of this writing.

Ainos (NASDAQ: AIMD ) stock is on the move Monday as the healthcare company's shares experienced heavy trading this morning. Ainos stock is experiencing strong pre-market trading on Monday as more than 7 million shares of the stock have changed hands.

Ainos (NASDAQ: AIMD ) stock is rocketing higher on Friday alongside heavy trading of the healthcare company's shares. Investors will note that more than 8 million shares of AIMD stock have changed hands as of this writing.

Ainos (NASDAQ: AIMD ) stock is on the rise Friday despite a lack of news from the medical technologies company. There have been no new press releases of filings with the Securities and Exchange Commission (SEC) that explain why AIMD stock is climbing today.

Use these tips for buying penny stocks after hours The post Tips for Buying Penny Stocks During After Hours appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which penny stocks are you watching right now? The post Buying Penny Stocks This Week?

Which penny stocks are on your buy list this week? The post New to Trading Penny Stocks?

Source: Shutterstock Ainos (NASDAQ: AIMD ) stock is gaining on Friday after seeing positive results from hamster trials of its Covid-19 treatment. These trials saw the company measuring the effectiveness of VELDONA over a 16-day period.